Abivertinib

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Name
Abivertinib
Accession Number
DB15327
Description

Abivertinib is under investigation in clinical trial NCT03300115 (Clinical Trial of the Efficacy and Safety of AC0010 in the Treatment of EGFR T790M Patients With Advanded NSCLC).

Type
Small Molecule
Groups
Investigational
Structure
Thumb
Weight
Average: 487.539
Monoisotopic: 487.213201268
Chemical Formula
C26H26FN7O2
Synonyms
Not Available
External IDs
  • AC0010

Pharmacology

Indication
Not Available
Contraindications & Blackbox Warnings
Learn about our commercial Contraindications & Blackbox Warnings data.
Learn More
Pharmacodynamics
Not Available
Mechanism of action
Not Available
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half-life
Not Available
Clearance
Not Available
Adverse Effects
Learn about our commercial Adverse Effects data.
Learn More
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Not Available
Food Interactions
Not Available

Products

Categories

Drug Categories
Classification
Not classified

Chemical Identifiers

UNII
CER0OPG92L
CAS number
1557267-42-1
InChI Key
UOFYSRZSLXWIQB-UHFFFAOYSA-N
InChI
InChI=1S/C26H26FN7O2/c1-3-23(35)29-17-5-4-6-19(15-17)36-25-20-9-10-28-24(20)31-26(32-25)30-18-7-8-22(21(27)16-18)34-13-11-33(2)12-14-34/h3-10,15-16H,1,11-14H2,2H3,(H,29,35)(H2,28,30,31,32)
IUPAC Name
N-{3-[(2-{[3-fluoro-4-(4-methylpiperazin-1-yl)phenyl]amino}-7H-pyrrolo[2,3-d]pyrimidin-4-yl)oxy]phenyl}prop-2-enamide
SMILES
CN1CCN(CC1)C1=CC=C(NC2=NC3=C(C=CN3)C(OC3=CC(NC(=O)C=C)=CC=C3)=N2)C=C1F

References

General References
Not Available
ChemSpider
57490375
BindingDB
294480
ZINC
ZINC000142081723

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
3WithdrawnTreatmentNon-Small Cell Lung Carcinoma (NSCLC)1
2Not Yet RecruitingTreatmentNovel Coronavirus Infectious Disease (COVID-19)1
2RecruitingTreatmentMetastatic Non-Small Cell Lung Cancer1
2RecruitingTreatmentNon-Small Cell Lung Carcinoma (NSCLC)1
1Active Not RecruitingTreatmentMetastatic Non-Small Cell Lung Cancer1
1CompletedTreatmentCarcinoma,Non-Small-Cell Lung / Non-Small Cell Lung Carcinoma (NSCLC)1
1CompletedTreatmentNon-Small Cell Lung Carcinoma (NSCLC)1
1RecruitingTreatmentLymphoma, B-Cell1
1, 2RecruitingTreatmentNon-Small Cell Lung Carcinoma (NSCLC)1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.0276 mg/mLALOGPS
logP4.33ALOGPS
logP4.82ChemAxon
logS-4.2ALOGPS
pKa (Strongest Acidic)12.6ChemAxon
pKa (Strongest Basic)7.25ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count6ChemAxon
Hydrogen Donor Count3ChemAxon
Polar Surface Area98.41 Å2ChemAxon
Rotatable Bond Count7ChemAxon
Refractivity138.95 m3·mol-1ChemAxon
Polarizability51.56 Å3ChemAxon
Number of Rings5ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterNoChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleYesChemAxon
Predicted ADMET Features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
Not Available

Drug created on May 20, 2019 09:15 / Updated on June 12, 2020 10:53

Logo pink
Are you a
new drug developer?
Contact us to learn more about our customized products and solutions.
Logo pink
Stay in the know!
As part of our commitment to providing the most up-to-date drug information, we will be releasing #DrugBankUpdates with our newly added curated drug pages.
#DrugBankUpdates